Market Research Logo

Conference Documentation: ADC Summit 2016

Conference Documentation: ADC Summit 2016

SMi proudly presents the return of the 5th annual ADC Summit to London in 2016!

With the FDA's recent approval of ADC's Adcetris® and Kadcyla ® , the industry has never been moving faster. The ADC market is anticipated to reach around US$ 12.7 Billion by 2020* and with most ADC research currently only in pre-clinical stages, we are yet to see the full market potential that ADCs are to contribute to the treatment of cancer. In an attempt to develop successors to Adcetris® and Kadcyla ® , the pharmaceutical industry is making every effort to produce the best next generation of ADCs by pioneering new approaches to eliminate cancer stem cells. As a result new innovations in conjugation methods and linker technology are bursting into the clinic at a rapid rate.

The introduction of second wave technology has seen a shift in industry from randomised cross linking technology to site directed technology, which has influenced a number of novel site specific conjugation techniques which have further influenced the next generation of ADCs. SMi's 5th annual ADC Summit brings you timely discussions to overcome ongoing challenges, including how to improve the therapeutic index of your ADC. Our 2-day event will provide a comprehensive analysis of the various approaches with the next generation ADCs. The conference will also focus on how to screen for optimal site of conjugation and offer some insight into how ADC can work in harmony with the field of oncology.


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc
9:10
Advancement in antibody drug conjugates: A step closer to magic bullets in war against cancer
Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc
9:50
Warheads for targeted therapies of cancer: strategies for designing and efficient synthesis of DNA cross-linkers
Iontcho Vlahov, Vice President of Discovery Chemistry, Endocyte, Inc.
10:30
Morning Coffee
11:00
Development of best-in-class, homogeneous ADCs for highly effective and safer cancer therapy
Roger Beerli, Chief Scientific Officer, NBE Therapeutics
11:40
Preclinical efficacy of a novel anti-C4.4a (LYPD3) antibody drug conjugate BAY 1129980 for the treatment of lung cancer
Joerg Willuda, Senior Scientist, Bayer
12:20
Networking Lunch
13:50
Producing Better ADCs Using ThioBridge™ Conjugation
George Badescu, Director of Scientific Affairs , Abzena
14:30
Novel site-specific conjugation tools
Thomas Keating, Director, Biochemistry, Immunogen, Inc.
15:10
Afternoon Tea
15:40
Expanding the scope of ADC targets through novel conjugation technologies
Sasha Koniev, CEO & Co Founder, Syndivia
16:20
Platform Technologies for Homogeneous and Versatile Protein Modification
Vijay Chudasama, Lecturer (Organic Chemistry and Chemical Biology), University College London
17:40
Chairman’s Closing Remarks and Close of Day One
Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.
9:10
ADCETRIS® (brentuximab vedotin) developed to treat Hodgkin
Ashish Gautam, Global Medical Lead - ADCETRIS, Takeda Pharmaceuticals
9:50
Predicting tissue distribution and clearance of antibody formats to improve selectivity of targeted therapies
Ben-Fillippo Krippendorff, Principal Scientist , Roche Pharmaceuticals
10:30
Morning Coffee
11:00
Impact of drug loading on ADC target binding and cytotoxicity
Debra Meyer, Senior Principal Scientist, Pfizer
11:40
Targeting Cadherin-6 (CDH6) with a novel antibody-drug conjugate for the treatment of ovarian and renal cancer”
Carl Uli Bialucha, Senior Investigator, Novartis Institutes For Biomedical Research
12:20
Networking Lunch
13:50
Engineering and development of novel immunotargeted nanotherapeutics
Daryl Drummond, Vice President, Discovery , Merrimack Pharmaceuticals Inc
14:30
The design, synthesis and scale-up of an ADC tubulysin payload
Jeremy Parker, Principal Scientist, AstraZeneca
15:10
Afternoon Tea
15:40
Challenges & lessons learnt in ADC CMC development and outsourcing
Jens Lohrmann, Principal Scientist, Novartis Biologics Analytical R&D, Novartis Biologics
16:20
FDCs (Fragment Drug Conjugates): A unique drug class or just smaller ADCs?
Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.
17:00
Chairman’s Closing Remarks and Close of Day Two
Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report